Literature DB >> 10353298

Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management.

E F Bowen1.   

Abstract

Patients with HIV are living longer now than in the past, and with a better quality of life. During the advanced stages of HIV infection patients are at risk of cytomegalovirus (CMV) reactivation and subsequently CMV disease. It is important to review the evidence on whether CMV reactivation leads to CMV disease and what the best methods are for detecting such a reactivation. CMV polymerase chain reaction (PCR) can be used qualitatively to predict CMV disease and quantitatively to predict a general increase in mortality. CMV PCR can also be used to direct either prophylaxis or pre-emptive therapy to those most at risk of CMV disease. CMV PCR should be an integral part of the decision-making process when treating both new patients with CMV retinitis and those with disease reactivation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353298     DOI: 10.2165/00003495-199957050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  21 in total

1.  Preemptive therapy in immunocompromised hosts.

Authors:  R H Rubin
Journal:  N Engl J Med       Date:  1991-04-11       Impact factor: 91.245

2.  Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis.

Authors:  E F Bowen; V C Emery; P Wilson; M A Johnson; C C Davey; C A Sabin; D Farmer; P D Griffiths
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

3.  Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.

Authors:  M Grzywacz; J R Deayton; E F Bowen; P Wilson; V C Emery; M A Johnson; P D Griffiths
Journal:  J Med Virol       Date:  1999-11       Impact factor: 2.327

4.  A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.

Authors:  J E Feinberg; S Hurwitz; D Cooper; F R Sattler; R R MacGregor; W Powderly; G N Holland; P D Griffiths; R B Pollard; M Youle; M J Gill; F J Holland; M E Power; S Owens; D Coakley; J Fry; M A Jacobson
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

5.  Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients.

Authors:  S A Spector; R Wong; K Hsia; M Pilcher; M J Stempien
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

6.  A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

Authors:  G M Schmidt; D A Horak; J C Niland; S R Duncan; S J Forman; J A Zaia
Journal:  N Engl J Med       Date:  1991-04-11       Impact factor: 91.245

7.  Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection.

Authors:  J J Zurlo; D O'Neill; M A Polis; J Manischewitz; R Yarchoan; M Baseler; H C Lane; H Masur
Journal:  Ann Intern Med       Date:  1993-01-01       Impact factor: 25.391

8.  Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification.

Authors:  S A Spector; R Merrill; D Wolf; W M Dankner
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

9.  Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS.

Authors:  D Salmon; F Lacassin; M Harzic; C Leport; C Perronne; F Bricaire; F Brun-Vezinet; J L Vilde
Journal:  J Med Virol       Date:  1990-11       Impact factor: 2.327

10.  Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.

Authors:  L Rasmussen; S Morris; D Zipeto; J Fessel; R Wolitz; A Dowling; T C Merigan
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

View more
  5 in total

1.  Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients.

Authors:  Junji Ikewaki; Eiichi Ohtsuka; Rie Kawano; Masao Ogata; Hiroshi Kikuchi; Masaru Nasu
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

2.  Development of real-time PCR assays for the quantitative detection of Epstein-Barr virus and cytomegalovirus, comparison of TaqMan probes, and molecular beacons.

Authors:  Jiska Jebbink; Xin Bai; Beverly Barton Rogers; D Brian Dawson; Richard H Scheuermann; Rana Domiati-Saad
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

3.  Polymerase chain reaction based detection of fungi in infected corneas.

Authors:  P A Gaudio; U Gopinathan; V Sangwan; T E Hughes
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

4.  Mononeuritis multiplex: an uncommon neurological manifestation of cytomegalovirus reactivation in an HIV-infected patient.

Authors:  Pedro Palma; Andreia Costa; Raquel Duro; Nélia Neves; Cândida Abreu; António Sarmento
Journal:  BMC Infect Dis       Date:  2018-11-12       Impact factor: 3.090

5.  CMV quantitative PCR in the diagnosis of CMV disease in patients with HIV-infection - a retrospective autopsy based study.

Authors:  Arne B Brantsaeter; Mona Holberg-Petersen; Stig Jeansson; Anne K Goplen; Johan N Bruun
Journal:  BMC Infect Dis       Date:  2007-11-06       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.